INFANRIX-IPV

This brand name is authorized in Ireland, New Zealand, Poland

Active ingredients

The drug INFANRIX-IPV contains a combination of these active pharmaceutical ingredients (APIs):

1 Tetanus toxoid UNII K3W1N8YP13 - CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Tetanus toxoid

2 Pertussis toxoid

Read about Pertussis toxoid

3 Pertussis filamentous hemagglutinin UNII 8C367IY4EY - BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Pertussis filamentous hemagglutinin

4 Pertactin UNII 2QNL82089R - BORDETELLA PERTUSSIS

Read about Pertactin

5 Inactivated poliovirus vaccine type I UNII 0LVY784C09 - POLIOVIRUS TYPE 1 ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Poliomyelitis, serotype 1

6 Inactivated poliovirus vaccine type II UNII 23JE9KDF4R - POLIOVIRUS TYPE 2 ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Poliomyelitis, serotype 2

7 Inactivated poliovirus vaccine type III UNII 459ROM8M9M - POLIOVIRUS TYPE 3 ANTIGEN (FORMALDEHYDE INACTIVATED)

Read about Poliomyelitis, serotype 3

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J07CA02	Diphtheria-pertussis-poliomyelitis-tetanus	J Antiinfectives for systemic use → J07 Vaccines → J07C Bacterial and viral vaccines, combined → J07CA Bacterial and viral vaccines, combined
Discover more medicines within J07CA02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 9752
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100147616